Structural Modeling of a Novel CAPN5 Mutation that Causes Uveitis and Neovascular Retinal Detachment

Alexander G. Bassuk1,2, Steven Yeh3, Shu Wu2, Daniel F. Martin4, Stephen H. Tsang5, Lokesh Gakhar6,7, Vinit B. Mahajan2,8*

1 Department of Pediatrics, University of Iowa, Iowa City, IA, United States of America, 2 Omics Lab, University of Iowa, Iowa City, IA, United States of America, 3 Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, United States of America, 4 Cole Eye Institute, Cleveland Clinic, Cleveland, OH, United States of America, 5 Bernard & Shirlee Brown Glaucoma Laboratory and Barbara & Donald Jonas Laboratory of Regenerative Medicine, Departments of Ophthalmology and Pathology and Cell Biology, Columbia University, New York, NY, United States of America, 6 Department of Biochemistry, University of Iowa, Iowa City, IA, United States of America, 7 Protein Crystallography Facility, University of Iowa, Iowa City, IA, United States of America, 8 Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, United States of America

* mahajanlab@gmail.com

Abstract

CAPN5 mutations have been linked to autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV), a blinding autoimmune eye disease. Here, we link a new CAPN5 mutation to ADNIV and model the three-dimensional structure of the resulting mutant protein. In our study, a kindred with inflammatory vitreoretinopathy was evaluated by clinical eye examinations, DNA sequencing, and protein structural modeling to investigate the disease-causing mutation. Two daughters of an affected mother demonstrated symptoms of stage III ADNIV, with posterior uveitis, cystoid macular edema, intraocular fibrosis, retinal neovascularization, retinal degeneration, and cataract. The women also harbored a novel guanine to thymine (c.750G>T, p.Lys250Asn) missense mutation in exon 6 of CAPN5, a gene that encodes a calcium-activated cysteine protease, calpain-5. Modeling based on the structures of all known calpains revealed the mutation falls within a calcium-sensitive flexible gating loop that controls access to the catalytic groove. Three-dimensional modeling placed the new mutation in a region adjacent to two previously identified disease-causing mutations, all three of which likely disrupt hydrogen bonding within the gating loop, yielding a CAPN5 with altered enzymatic activity. This is the third case of a CAPN5 mutation leading to inherited uveitis and neovascular vitreoretinopathy, suggesting patients with ADNIV features should be tested for CAPN5 mutations. Structural modeling of novel variants can be used to support mechanistic consequences of the disease-causing variants.
Introduction

Mendelian forms of autoimmune disease are rare. In two large, unrelated kindreds we recently identified the first mutation shown to cause nonsyndromic uveitis: coding mutations in \textit{CAPN5} caused an inherited uveitis called autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV, OMIM #602537) [1]. ADNIV is characterized by progressive, severe intraocular inflammation, photoreceptor degeneration, retinal neovascularization, intraocular fibrosis, and retinal detachment. Otherwise, affected patients have no associated systemic conditions.

\textit{CAPN5} encodes calpain-5, a calcium-activated signaling protease expressed by retinal photoreceptors [1]. ADNIV-associated mutations in calpain-5 reside in a flexible loop gating the active site and are expected to alter enzymatic activity, likely leading to a gain of function [1]. Since the substrate of calpain-5 has not been identified, however, a functional assay for calpain 5 is not currently available. Nevertheless, for calpains in general, excess activity is associated with retinal and cell degeneration [2–4]. Accordingly, expressing mutant calpain-5 alleles only in the mouse retina is sufficient to trigger disease [5], while deleting the gene (in the knockout mouse) does not result in a phenotype [6]. In this study, we identify a new \textit{CAPN5} mutation in a third ADNIV family and model the functional effect of this mutation on the protein structure.

Methods

Subjects provided written informed consent under a study approved by the University of Iowa’s Institutional Review Board, and the study adheres to the tenets set forth in the Declaration of Helsinki. Subjects underwent eye exams that included slit-lamp examination, dilated retinal biomicroscopy and indirect ophthalmoscopy, optical coherence tomography, and in selected cases, fluorescein angiography (FFA) and electroretinography (ERG).

DNA Sequencing and Analysis

Saliva was collected using Oragene sample collection kits (DNAgenotek, Ontario, Canada), and DNA was extracted by salt precipitation. PCR primers were designed as previously described [1], and products were analyzed with a 3730 DNA sequencer and GeneMapper software (Applied Biosystems).

Structural Analysis

Primary and secondary structure protein alignments and trees were created with Geneious Pro 5.4.6 (http://www.geneiouspro.com). A BLAST search for the catalytic core of calpain-5 against the Protein Database (PDB) returned the structures of the catalytic cores of human calpain-9 with (PDB ID 2P0R; formed catalytic site) and without leupeptin bound (1ZIV; unformed catalytic site) leupeptin bound as the top hits. The sequence identity between target and template sequences was 42%. Other close matches are the catalytic cores of rat calpain-1 with (1TL9) and without leupeptin (1QXP), human calpain-1 (2ARY), human calpain-2 (1KFX), rat calpain-2 (1DF0) and human calpain-8 (2NQA). Homology models were generated using MODELLER 9.14 with the human calpain-9 catalytic cores [7]. The align2d.py python script, which is part of the MODELLER package, was used to generate an alignment between the human calpain-5 and calpain-9 catalytic cores. The model-single.py python script from the MODELLER package was then used to generate 10 models, each using the human calpain-9 catalytic cores (2P0R — apo and 1ZIV — leupeptin bound) as templates. The ten calpain-5 models within each group superimposed well with most variations in loops far away from the ADNIV mutation site. The rmsd over about 260 C\(\alpha\) atoms ranged between 0.128–0.232 for the apo template.
models and between 0.078–0.132 for the leupeptin-bound template models. While the apo and leupeptin-bound template models differed significantly (rmsd of ~ 6.6), this was because of the domain movements on leupeptin binding. The individual domains IIa and IIb align individually quite well with rmsds of 0.435 and 0.566 respectively. Since there was very little variation in the region around our ADNIV mutation site of interest, we picked the top model generated by MODELLER based off the apo-template as a representative model for figures. PyMOL was used to generate all structure figures [8].

Results
Phenotypic Ascertainment

The proband (II:1) was a 26 year-old female who began to lose vision at age 23. She was diagnosed with noninfectious uveitis with recurrent cystoid macular edema (CME) OU. At the time of her initial presentation, best-corrected visual acuity measured 20/40 OD and 20/200 OS. There was no relative afferent pupillary defect, and intraocular pressures were 12 mmHg OU. Anterior segment examination revealed quiet anterior chambers, 2+ nuclear sclerotic cataracts OU and 1+ posterior subcapsular cataract OS. Dilated funduscopic exam showed 2+ vitreous cell OU, 1+ vitreous haze OS with cystoid macular edema OU (Fig 1), but no bone-spicule pigmentation or pigment clumping, and the periphery was well vascularized. Despite periocular corticosteroid injections and triamcinolone acetonide injections, there was recurrent CME and vitreous inflammation. Over the next six years, she underwent several surgeries in both eyes. These included fluocinolone acetonide (FA) implantation OU for her uveitis and CME, phacoemulsification and intraocular lens implantation for cataracts, Ahmed tube shunts for steroid-response glaucoma, and vitrectomies for vitreomacular traction and epiretinal membranes. She maintained 20/50 OD and 20/100 OS vision for five years until she developed a dense non-clearing vitreous hemorrhage with a tractional detachment associated with peripheral neovascularization OD. This was repaired with vitrectomy, and because of recurrent vitreous hemorrhage in the context of recurrent inflammation, she underwent repeat vitrectomy and repeat FA implantation OU. One year later, her visual acuity measured 20/80 OD and 20/50 OS. She now had diffuse pigmentary spots throughout the peripheral retina. A full-field ERG showed non-recordable cone and rod responses indicative of severe photoreceptor dysfunction OU.

The proband’s sister (II:2) began to lose vision at age 20, also due to noninfectious uveitis. She had undergone surgery for vitreomacular traction and epiretinal membranes OU and cataracts. Her best-corrected visual acuity measured 20/50 OD and 20/30 OS. There was no relative afferent pupillary defect, and intraocular pressures were 16 mmHg OD and 18 mmHg OS. Anterior segment examination revealed subepithelial corneal haze, trace anterior chamber cells, and posterior chamber intraocular lenses OU. Dilated funduscopic examination showed 1+ vitreous cells and a recurrent epiretinal membrane with cystoid macular edema OD (Fig 1). The patient’s VA was maintained at 20/50 OD and 20/40 OS for five years until a decline to 20/150 OD. She developed a dense fibrotic membrane over the macula and a shallow, inferior, 5 clock-hour macula--off rhegmatogenous and tractional retinal detachment. The patient underwent a scleral buckle with cryotherapy OD. Minimal subretinal fluid was present on postoperative day 1. However, on postoperative day 6, she developed an inferior exudative retinal detachment and her vision was reduced to hand motions. Oral prednisone at 60 mg/day was initiated and tapered over six weeks; the exudative RD resolved and an improvement in her visual acuity to 20/125 at postoperative month three. Over the next two years, she underwent two vitrectomies and intravitreal dexamethasone implants for recurrent epiretinal membranes and CME. Nevertheless, her visual acuity declined to 20/400 and the CME recurred. Here left eye showed a similar decline.
The sisters’ mother was reported to have similar vision loss resulting in blindness. Their father and two uncles were not affected (Fig 1). The combination of relentless posterior uveitis, recurrent CME and epiretinal membranes, peripheral pigmentary degeneration, tractional retinal detachment and retinal neovascularization was consistent with Stage III ADNIV in two
large pedigrees we previously described. There was no relation to either of these families. The inheritance pattern was compatible with a highly penetrant, dominant Mendelian disease.

**Mutation analysis**

Because of the phenotypic similarity to other ADNIV cases, the **CAPN5** coding region of the family members was sequenced. A heterozygous guanine to thymine nucleotide variant, resulting in a lysine to asparagine substitution (at genomic position Chr11:77115445, NM_004055.4: c.750G>T, p.Lys250Asn), was found in both affected subjects but none of the unaffected (Fig 2). This variant was not present in the dbSNP or 1000 Genome databases. In addition, the variant allele was not found in the over 13,000 **CAPN5** alleles sequenced in the NHLBI Exome Sequencing Project [9].

**Structural Analysis of Calpain-5 ADNIV Mutations**

Calpain-5 is a calcium-activated cysteine protease with evolutionarily conserved residues and domains required for protease activity. The calpain-5 catalytic domain-II is encoded by exon-6, where we previously identified two disease-causing **CAPN5** mutations. The newly identified c.750G>T mutation was also found in exon-6, and mutates Lys250, which is within six amino acids of the known mutations and one amino acid away from the catalytic histidine residue. Lys250 is conserved in nearly 100% of vertebrate orthologs. Among the 13 human paralogs, Lys250 is conserved in seven, and in two other calpains the protein has an identically charged arginine (Fig 2).

The targets of calpain-5 have not been identified and there is no established method for its purification and activity measurement. Since there is no functional assay for calpain-5, we examined how the new ADNIV p.Lys250Asn mutation is structurally related to functional residues in the catalytic domain-II. Homology modeling to calpain-9 generated a three-dimensional structure for the calpain-5 catalytic core (Fig 3) [10, 11]. The two previously identified calpain-5 mutations (p.Arg243Leu, p.Leu244Pro) were modeled as part of a short beta sheet in a flexible gating loop that undergoes calcium-induced conformation changes during enzyme activation (Fig 3). (This location is in contrast to the original homology model that placed these residues in the loop’s alpha helix.) This loop is located on the 5-prime side of the catalytic groove and controls access to substrates. Interestingly, the new calpain-5 mutation sits deeper within the catalytic groove but on the same loop. In the primary sequence, the prior two ADNIV mutations are separated from the newly identified mutation, but when modeled in three-dimensions, the three mutations lie very near one another (Fig 3).

The gating loop has been found in variable conformations in almost all other calpain crystal structures or left unmodeled due to poor electron density [10, 12–16], indicating that it is highly flexible (Fig 4). Considering the floppy nature of the loop harboring the ADNIV mutations, and the lack of conservation in this stretch [10, 12–16], no single model or template completely captures the different conformations this loop can adopt. However, both the apo and leupeptin bound structures for calpain-9, which best matches the 9-residue stretch spanning the three ADNIV mutations in calpain-5, has this segment of the loop locked in an identical conformation. Therefore, in the context of the catalytic site formation and maintenance, we believe the homology model based on calpain-9 (Fig 5) provides a better perspective on the effect of all the ADNIV mutations identified so far [1]. Since calpains do not have a rigid active site, our structural findings suggest that mutations in this flexible gating loop affect calpain-5 activity. Our identification of a third disease-causing mutation in this same loop supports the idea that the loop provides a mechanism for regulating enzymatic activity [14–16].
Fig 2. The CAPN5 gene harbors a novel mutation in exon-6. A. Chromatogram of proband showed a heterozygous c.750G>T DNA sequence mutation (arrow) in exon 6 of CAPN5. B. Calpain-5 is composed of four domains, and the mutation was located in catalytic domain IIb (green). C. Primary protein sequence alignment of calpain-5 orthologs shows high evolutionary conservation of the new mutated p.Lys250Asn residue, along with the two prior ADNIV mutations, p.Arg243Leu and p.Leu244Pro (red arrow/box) in catalytic domain IIb. The two previously identified ADNIV mutations and the newly identified ADNIV mutation are 2 to 9 amino acids upstream of the histidine catalytic residue (blue box). Amino acid mismatches are color-highlighted. D. Twelve human calpain family paralogs show the p.Lys250Asn is highly conserved. (Black, 100% similarity; dark grey, 80 to 100% similarity; light grey, 60 to 80% similarity; white, less than 60% similarity).

doi:10.1371/journal.pone.0122352.g002
The two known ADNIV mutations, p.Arg243Leu and p.Leu244Pro, are at highly conserved residues of calpain-5 orthologs and significantly alter the structure of the gating loop by introducing a hydrophobic leucine in place of a positively charged arginine (p.Arg243Leu) or replacing a hydrophobic residue with a rigid proline (p.Leu244Pro). These mutations likely affect the formation of the alpha helix and beta sheet within this gating loop also observed in other calpain crystal structures and the homology model of calpain-5 (Fig 4) [1].
Our newly identified p.Lys250Asn mutation replaces a longer, positively charged residue with a shorter, polar residue. This modifies an essential hydrogen bond that appears to be necessary for active-site formation and catalysis. Interestingly, eight of the nine calpain-5 paralogs with a conserved positively charged residue at the Lys250 position (Lys252 for calpain-9; Fig 2) also have a conserved negatively charged residue (Asp239 for calpain-5, Glu241 for calpain-9) on a short alpha-helix with which it forms a salt bridge (Fig 5). This Asp/Glu in turn hydrogen bonds with the backbone nitrogen of Val235 (Arg237 for calpain-9; Fig 5), suggesting a hydrogen bond network locks the loop in place. The hydrogen bonding capability of the shorter, polar mutant asparagine is quite different from the longer, positively charged lysine it replaces (Fig 5). The asparagine has the potential to form two hydrogen bonds instead of the single one that lysine can form; this should affect the interaction with Asp239. Taken together, these
results suggest that amino acid variants in the region adjacent to the catalytic histidine are not likely to be deleterious, but instead affect the flexible gating loop and catalytic groove, thereby modifying enzymatic activity.

**Discussion**

A new, non-synonymous heterozygous mutation in *CAPN5* was identified in clinically affected members of a third family with ADNIV. The clinical phenotype in these patients was similar to the two kindreds reported previously. This new ADNIV family responded to FA implantation in the same way as our other ADNIV patients [17, 18]: FA therapy controlled inflammation and neovascularization, but there was recurrent fibrosis, tractional detachment, and retinal degeneration. Similar to the patients in this report, we have observed asymmetric disease progression between eyes of ADNIV twins [19]. Our combined studies on ADNIV and *CAPN5* mutations suggest that all patients with an ADNIV phenotype should undergo genetic testing for *CAPN5* mutations.

Genes that cause monogenic disorders also harbor polymorphisms that are associated with more common and sometimes less severe disease. It will be important to determine whether any *CAPN5* polymorphisms are risk factors for patients with the ADNIV-like diseases, such as uveitis, diabetic retinopathy, retinitis pigmentosa, or proliferative vitreoretinopathy. Genetic association studies, for example, have identified *CAPN5* variants that are risk factors for type II diabetes, hypertension, high cholesterol, and polycystic ovary syndrome [2, 20–22].

Calpains require careful regulation since they target multiple intracellular proteins and pathways [23–26]. An unregulated calpain-5 could simultaneously activate different intracellular pathways. In comparison to caspases that activate apoptotic, noninflammatory cell death pathways, calpains activate necrotic, inflammatory cell death pathways [27]. This could explain why *CAPN5* retinal degeneration displays a uveitic vitreoretinopathy instead of a noninflammatory photoreceptor degeneration typical of retinitis pigmentosa. The finding that FA therapy treats some calpain-5 effects supports the concept that calpain-5 activates multiple downstream pathways. Nevertheless, the target protein substrates for many calpains, including...
calpain-5, have yet to be identified [28]. Unless CAPN5 is directly targeted [29], combination therapies will be required to address the other pathways that trigger photoreceptor degeneration and intraocular fibrosis.

When visualized in the context of the high-resolution, three-dimensional atomic structures, seemingly disparate single mutations, which lie separately along the primary protein sequence, can often be put into perspective. Modeling may be especially illuminating when there is no bioassay to ascertain the effect of a genetic variant. In the absence of experimentally determined structures, suitable templates from the growing number of structures in the PDB can yield homology models that are a good proxy. As we report here, all of the ADNIV mutations identified so far fall in a flexible gating loop and cluster next to the catalytic site; they seemingly affect the formation or movement of this loop during ligand binding or catalysis. In three dimensions, these three mutations cluster together and are part of a backbone or side-chain-mediated hydrogen bond network. The model strongly supports the notion that structure of this peptide loop controls calpain-5 enzymatic activity or specificity. The flexible loops are the most variable region among calpains, and are thought to account for enzymatic differences among calpain isoforms [15, 16, 23]. Minor amino acid substitutions could result in subtle alterations in specificity and catalytic activity differences between isoforms, as well as in disease-causing mutations. It would be worthwhile to genetically screen for variants in CAPN5 and model them onto a three-dimensional calpain-5 structure to study the commonality of disease-causing mechanisms.

Clinical sequencing is producing a wealth of data, but the functional consequences of the results can often be challenging to interpret. Structural modeling offers insight into underlying pathobiology but, by itself, modeling has limitations. The most powerful genotype-phenotype insights can be made in cases such as the present study, when rigorous clinical phenotype observations coincide with structural analyses.

**Author Contributions**

Conceived and designed the experiments: AGB SHT LG VBM. Performed the experiments: AGB SY SW DFM SHT LG VBM. Analyzed the data: AGB SY SW DFM SHT LG VBM. Contributed reagents/materials/analysis tools: AGB SY SW DFM SHT LG VBM. Wrote the paper: AGB SY SW DFM SHT LG VBM.

**References**

1. Mahajan VB, Skeie JM, Bassuk AG, Fingert JH, Braun TA, Daggett HT, et al. Calpain-5 mutations cause autoimmune uveitis, retinal neovascularization, and photoreceptor degeneration. PLoS Genet. 2012; 8: e1003001. doi:10.1371/journal.pgen.1003001 PMID: 23055945
2. Huang Y, Wang KK. The calpain family and human disease. Trends Mol Med. 2001; 7: 355–362. PMID: 11516996
3. Azuma M, Shearer TR. The role of calcium-activated protease calpain in experimental retinal pathology. Surv Ophthalmol. 2008; 53: 150–163. doi: 10.1016/j.survophthal.2007.12.006 PMID: 18348880
4. Vanderklish PW, Bahr BA. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int J Exp Pathol. 2000; 81: 323–339. PMID: 11168679
5. Wert KJ, Skeie JM, Bassuk AG, Olivier AK, Tsang SH, Mahajan VB. Functional validation of a human CAPN5 exome variant by lentiviral transduction into mouse retina. Hum Mol Genet. 2014; 23: 2665–2677. doi: 10.1093/hmg/ddt661 PMID: 24381307
6. Franz T, Winckler L, Boehm T, Dear TN. Capn5 is expressed in a subset of T cells and is dispensable for development. Mol Cell Biol. 2004; 24: 1649–1654. PMID: 14749380
7. Eswar N, Marti-Renom MA, Webb B, Madhusudhan MS, Eramian D, Shen M-y, et al. Comparative Protein Structure Modeling with Modeller. Current Protocols in Bioinformatics. Suppl. 15. Hoboken, NJ: John Wiley & Sons, Inc.; 2006. p. 5.6.1–5.6.30.
8. PyMOL. New York: Schrödinger; 2014 [cited 11 February 2015]. Available: http://www.pymol.org/.
9. NHLBI Exome Sequencing Project (ESP). Exome Variant Server. Seattle, WA; 2011 [cited 11 December 2011]. Available: http://evs.gs.washington.edu/EVS/.

10. Hanna RA, Campbell RL, Davies PL. Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin. Nature. 2008; 456: 409–412. doi: 10.1038/nature07451 PMID: 19020623

11. Moldoveanu T, Gehring K, Green DR. Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. Nature. 2008; 456: 404–408. doi: 10.1038/nature07353 PMID: 19020622

12. Moldoveanu T, Hosfield CM, Lim D, Elce JS, Jia Z, Davies PL. A Ca(2+) switch aligns the active site of calpain. Cell. 2002; 108: 649–660. PMID: 11893336

13. Moldoveanu T, Gehring K, Green DR. Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. Nature. 2008; 456: 404–408. doi:10.1038/nature07353 PMID: 19020622

14. Moldoveanu T, Campbell RL, Cuerrier D, Davies PL. A Ca(2+) switch aligns the active site of calpain. Cell. 2002; 108: 649–660. PMID:11893336

15. Moldoveanu T, Hosfield CM, Lim D, Elce JS, Jia Z, Davies PL. Calpain silencing by a reversible intrinsic mechanism. Nat Struct Biol. 2003; 10: 371–378. PMID: 12665854

16. Moldoveanu T, Hosfield CM, Lim D, Jia Z, Davies PL. Crystal structures of calpain-E64 and-leupeptin inhibitor complexes reveal mobile loops gating the active site. J Mol Biol. 2004; 343: 1313–1326. PMID: 15491615

17. Croall DE, Ersfeld K. The calpains: modular designs and functional diversity. Genome Biol. 2007; 8: 218. PMID: 17608959

18. Campbell RL, Davies PL. Structure-function relationships in calpains. Biochem J. 2012; 447: 335–351. doi:10.1042/BJ20120921 PMID: 23035980

19. Tlucek PS, Folk JC, Orien JA, Stone EM, Mahajan VB. Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy. Arch Ophthalmol. 2012; 130: 1395–1401. doi:10.1001/archophthalmol.2012.1971 PMID: 22777573

20. Rowell HA, Bassuk AG, Mahajan VB. Monozygotic twins with CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy. Clin Ophthalmol. 2013; 7: 1093–1098. doi: 10.2147/OPTH.S43939 PMID: 23785231

21. Baier LJ, Permana PA, Yang X, Pratley RE, Hanson RL, Shen GQ, et al. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest. 2000; 106: R69–73. PMID: 11018080

22. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000; 26: 163–175. PMID: 11017071

23. Sáez ME, Martínez-Larrad MT, Ramírez-Lorca R, González-Sánchez JL, Zabena C, Martínez-Calatrava MJ, et al. Calpain-5 gene variants are associated with diastolic blood pressure and cholesterol levels. BMC Med Genet. 2007. doi:10.1186/1471-2350-8-1

24. Croall DE, DeMartino GN. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol Rev. 1991; 71: 813–847. PMID: 2057527

25. Sato K, Kawashima S. Calpain function in the modulation of signal transduction molecules. Biol Chem. 2001; 382: 743–751. PMID: 1117927

26. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003; 83: 731–801. PMID: 12843408

27. Zatz M, Starling A. Calpains and disease. N Engl J Med. 2005; 352: 2413–2423. PMID: 15944426

28. Syntichaki P, Xu K, Driscoll M, Tavernarakis N. Specific aspartyl and calpain proteases are required for neurodegeneration in C. elegans. Nature. 2002; 419: 939–944. PMID: 12410269

29. DuVerle DA, Ono Y, Sorimachi H, Mamitsuka H. Calpain cleavage prediction using multiple kernel learning. PLoS One. 2011; 6: e19035. doi:10.1371/journal.pone.0019035 PMID: 21559271

30. Nelson NG, Skeie JM, Muradov H, Rowell HA, Seo S, Mahajan VB. CAPN5 gene silencing by short hairpin RNA interference. BMC Res Notes. 2014; 7: 642. doi: 10.1186/1756-0500-7-642 PMID: 25216694